Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

OBJECTIVES: The ALIGN study (NCT01061723) evaluated the efficacy and safety of sarilumab, the first fully human monoclonal antibody against interleukin-6 receptor-α (IL-6Rα), in patients with ankylosing spondylitis (AS). METHODS: Patients with active AS despite conventional treatment were randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieper, Joachim, Braun, Jürgen, Kay, Jonathan, Badalamenti, Salvatore, Radin, Allen R, Jiao, Lixia, Fiore, Stefano, Momtahen, Tanya, Yancopoulos, George D, Stahl, Neil, Inman, Robert D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431338/
https://www.ncbi.nlm.nih.gov/pubmed/24550171
http://dx.doi.org/10.1136/annrheumdis-2013-204963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431338/
https://www.ncbi.nlm.nih.gov/pubmed/24550171
http://dx.doi.org/10.1136/annrheumdis-2013-204963

Ejemplares similares